Comparative Pharmacology
Head-to-head clinical analysis: CATHFLO ACTIVASE versus KINLYTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CATHFLO ACTIVASE versus KINLYTIC.
CATHFLO ACTIVASE vs KINLYTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tissue plasminogen activator that converts plasminogen to plasmin, leading to fibrinolysis.
Anticholinergic; muscarinic receptor antagonist; reduces gastrointestinal motility and secretion.
2 mg via intracatheter instillation, dwell for 2 hours, then aspirate; may repeat once if occlusion persists. For occluded central venous access devices only.
100 mg orally twice daily, with or without food.
None Documented
None Documented
Initial half-life: 4–6 minutes (alpha phase); terminal half-life: 30–50 minutes (beta phase). Clinical context: Rapid clearance from plasma; effects on fibrinogen depletion persist for 12–24 hours.
Terminal elimination half-life: 12–18 hours; steady-state achieved within 3 days; allows once-daily dosing.
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for <5% of the dose. Biliary/fecal elimination is minimal (<1%).
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; 94% recovered in feces over 10 days, mostly as metabolites.
Category C
Category C
Thrombolytic Agent
Thrombolytic Agent